Singular Genomics Systems, Inc.: directors' dealings · United States · SEC (Form 4)

About Singular Genomics Systems, Inc.

Singular Genomics Systems, Inc. is a U.S.-based life science technology company that was listed on the Nasdaq under the ticker OMIC. The company was incorporated in Delaware in 2016 and built its core operations in La Jolla, California, positioning itself as a precision-sequencing and spatial multiomics platform company rather than a traditional pharma developer. Its public filings describe a business focused on enabling researchers and clinicians through proprietary next-generation sequencing and tissue-based analysis technologies. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1850906/000095017022003570/omic-20211231.htm)) At the center of Singular’s model is its proprietary “Sequencing Engine,” a technology base designed to improve speed, accuracy, flexibility, and throughput. From that foundation, the company developed the G4, a benchtop next-generation sequencer targeted at applications such as oncology, immune profiling, single-cell research, and broader genomics workflows. Singular also advanced a second major platform, originally referred to as PX and later highlighted commercially as the G4X Spatial Sequencer, which combines sequencing with spatial analysis, proteomics, and multiomic readouts from tissue samples. In 2024, the company unveiled the G4X and framed it as a platform for high-throughput in situ RNA sequencing, targeted transcriptomics, and proteomics profiling from FFPE tissue. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1850906/000095017022003570/omic-20211231.htm)) From a competitive standpoint, Singular occupied a specialized segment of the genomics tools market, where it faced larger, better-capitalized incumbents but differentiated itself through the promise of a dual-purpose instrument that could support both conventional NGS and spatial biology applications. That strategic combination is important for labs and translational research customers looking to consolidate workflows and improve analytical depth without moving across multiple platforms. The company’s product-led strategy also included consumables and related workflows, which are important for long-term customer stickiness and recurring revenue potential. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1850906/000095017022003570/omic-20211231.htm)) Geographically, Singular’s business was centered in the United States, with headquarters and principal operations in La Jolla, California, and a manufacturing/facilities buildout tied to that site. The company’s commercial communications in 2024 emphasized expanding spatial services and preparing for broader G4X commercialization, signaling a transition from instrument development toward platform adoption and services support. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1850906/000119312521233969/d199258dex991.htm)) A major recent development was the acquisition agreement with Deerfield Management announced on December 23, 2024, at $20.00 per share in cash, followed by completion of the merger on February 21, 2025. As a result, OMIC is no longer trading as an independent Nasdaq-listed security, but its SEC Form 4 insider transaction history remains relevant for investors analyzing management behavior, dilution, and historical capital-markets signals. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1850906/000119312525038756/d923657dex991.htm?utm_source=openai))